Loqtorzi is a cancer medicine used in adults to treat: - nasopharyngeal cancer (cancer of the nasopharynx, where the throat and nose connect) that is recurrent (has come back) and cannot be treated with surgery or radiotherapy or is metastatic (has spread to other parts of the body). It is used together with cisplatin and gemcitabine, other cancer medicines (also known as chemotherapy); - oesophageal squamous cell cancer, a type of cancer affecting the oesophagus (the passage from the mouth to the stomach). It is used when the cancer is advanced and cannot be removed by surgery or if it is recurrent or metastatic. It is used together with the chemotherapy medicines cisplatin and paclitaxel. Loqtorzi contains the active substance toripalimab.
Therapeutic Indication
### Therapeutic indication Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Therapeutic Area (MeSH)
ATC Code
L01FF13
ATC Item
toripalimab
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Loqtorzi
Medicine Name
Loqtorzi
Aliases
N/ANo risk management plan link.
